Solid. Experienced. Motivated.
Led by a team of cross-functional domain experts.
CIO & Managing Partner
Mr. Sarrazin is Chief Investment Officer and Managing Partner of the Autism Impact Fund where he oversees the firm and leads AIF’s Life Sciences practice. Rob’s career as a longtime healthcare investor, private equity partner and corporate development executive includes decades of experience overseeing a large portfolio of control investments, including corporate strategic transactions and over 30+ middle market growth acquisitions under multiple private equity funds.
An innovative and patient-oriented scientist, Ashok Srinivasan has an extensive history of leadership in clinical and basic science.
As the Translational Research Scientist for NSABP Foundation/NRG Pittsburgh, Ashok has dedicated the past seven years to translating scientific advances to clinical trials, supporting new technology and therapeutic advancements for breast and colorectal cancer. In this role, Ashok has consulted as a molecular genetics / genomics expert in developing scientific rationales for 10+ clinical trials and educated clinical trialists on emerging trends and best practices in
Mr. Male is Co-Founder and Managing Partner of the Autism Impact Fund where he oversees the firm and leads the Business Services practice. Chris has over ten years experience leading venture and middle-market equity financing across business services, impact, and real estate, most recently as Managing Director of RBG Capital, LLC, his family's private investment arm.
Katie Mangialardi, Associate, invests on behalf of the firm’s Life Sciences and Life Span Services divisions, and has spent her career working at the intersection of healthcare and finance. Katie was previously an Associate at J.P.Morgan, where she worked across both Derivatives Sales and Acquisition Leveraged Finance.
Katie holds a B.S. in Biology of Global Health from Georgetown University, where she was a George F. Baker Scholar. She resides in New York.
INVESTMENT ADVISORY TEAM
“Venture capital is the accelerant that brings breakthrough technologies into markets. With millions of kids and
adults suffering from severe medical and
physiological challenges due to autism, now is
the time for the Autism Impact Fund.”
- Sean O’Sullivan, AIF Advisor & Founding LP
SCIENTIFIC ADVISORY BOARD
Krishnan Nandabalan, PhD
Bold strategy + Biology + Technology = Audacious goal achieved.